Advertisement
Screener

Pyxis Oncology, Inc. (PYXS) Operating Lease Right-of-Use Assets

2.8 / 5 stars · 68/120 Roast Me

Pyxis Oncology, Inc. Operating Lease Right-of-Use Assets

Pyxis Oncology, Inc. (PYXS) had Operating Lease Right-of-Use Assets of $10.95 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13

  • 2026-06-30: Operating Lease, Right-of-Use Asset $10.95M.
  • 2026-03-31: Operating Lease, Right-of-Use Asset $11.19M.
  • 2025-12-31: Operating Lease, Right-of-Use Asset $11.42M.
  • 2025-09-30: Operating Lease, Right-of-Use Asset $11.64M.
Period endOperating Lease, Right-of-Use Asset
2026-06-30$10.95M
10-Q · filed 2026-08-13
2026-03-31$11.19M
10-Q · filed 2026-05-14
2025-12-31$11.42M
10-Q · filed 2026-08-13
2025-09-30$11.64M
10-Q · filed 2025-11-03
2025-06-30$11.85M
10-Q · filed 2025-08-14
2025-03-31$12.05M
10-Q · filed 2025-05-15
2024-12-31$12.24M
10-K · filed 2026-03-23
2024-03-31$12.78M
10-Q · filed 2024-05-14
2023-12-31$12.94M
10-K · filed 2025-03-18
2023-09-30$13.13M
10-Q · filed 2023-11-07
2023-06-30$13.28M
10-Q · filed 2023-08-11
2023-03-31$13.46M
10-Q · filed 2023-05-11
2022-12-31$13.60M
10-K · filed 2024-03-21
2022-09-30$14.70M
10-Q · filed 2022-11-01
2022-06-30$15.00M
10-Q · filed 2022-08-15
2022-04-01$15.30M
10-K · filed 2023-03-22
2021-12-31$232.00K
10-K · filed 2023-03-22
2021-09-30$388.00K
10-Q · filed 2021-11-15
2020-12-31$836.00K
10-K · filed 2022-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55